Literature DB >> 30552617

The expression levels of miRNA-15a and miRNA-16-1 in circulating tumor cells of patients with diffuse large B-cell lymphoma.

Seref Bugra Tuncer1, Demet Akdeniz1, Betul Celik1, Seda Kilic1, Ozge Sukruoglu1, Mukaddes Avsar1, Leyla Ozer2, Meltem Ekenel2, Sevda Ozel3, Hulya Yazici4.   

Abstract

MicroRNAs (miRNAs) have major roles in nearly all cellular process including gene expression, and may behave as oncogene or tumor suppressor gene by binding to complementary sequences in the target mRNA. The circulating microRNA-15a (miRNA-15a) and microRNA-16-1 (miRNA-16-1) of 15 healthy adults and of 40 untreated patients diagnosed with diffuse large B-cell lymphoma (DLBC) were recruited to investigate the expression levels. The expression levels of miRNA-15a, and miRNA-16-1 genes of the untreated DLBCL patients, and healthy individuals with matched age, sex and ethnicity were examined. MicroRNA expression profiles obtained from peripheral blood were investigated. The samples were collected from 40 patients diagnosed with DLBC patients, and from 15 healthy controls. Two miRNAs were selected, and expression profile was examined using a quantitative real-time polymerase chain reaction (qPCR) based on the previous studies. Statistically significant expression level differences (p < 0.05) were detected for miRNA-16-1 in DLBCL patients and healthy control groups. miRNA-16-1 gene expression level was found approximately ninefold higher in the patient group compared to the controls; however, no statistical difference was detected in the expression profile of miRNA-15a between the both groups. On the other hand, the decreased gene expression in miRNA16-1 was observed in 88.3% of DLBCL patients. These results suggested that there was no statistically significant decrease in the miRNA-15a gene expression in DLBCL patients (p > 0.05). On the contrary to the literature, miRNA-16-1 expression level was suppressed in DLBCL group in our study, however no whole gene silencing was performed. MicroRNA-16-1 might be suggested to behave as a tumor suppressor in DLBCL in our study.

Entities:  

Keywords:  Circulating tumor cells; Diffuse B-cell non-Hodgkin lymphoma; MicroRNAs; miRNA-15a; miRNA-16-1

Mesh:

Substances:

Year:  2018        PMID: 30552617     DOI: 10.1007/s11033-018-4554-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  8 in total

1.  Evaluation of the promoter methylation status of hypoxia factor 3A and interleukin-6 genes and expression levels of mir-130b and mir-146b in childhood obesity.

Authors:  Esra Tekcan; Nurten Kara; Hasan Murat Aydın; Ümmet Abur; Mohsen Abbaszadeh
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-09       Impact factor: 1.712

2.  MicroRNA-361-3p Inhibit the Progression of Lymphoma by the Wnt/β-Catenin Signaling Pathway.

Authors:  Hui Zhou; Huifeng Tang; Ning Li; Hang Chen; Xiaohui Chen; Lei Gu; Liang Zhang; Guoyan Tian; Diehong Tao
Journal:  Cancer Manag Res       Date:  2020-12-02       Impact factor: 3.989

3.  Downregulation of microRNA-16-5p accelerates fracture healing by promoting proliferation and inhibiting apoptosis of osteoblasts in patients with traumatic brain injury.

Authors:  Yun Sun; Yuan Xiong; Chenchen Yan; Lang Chen; Dong Chen; Bobin Mi; Guohui Liu
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

Review 4.  Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review.

Authors:  Philippe Decruyenaere; Fritz Offner; Jo Vandesompele
Journal:  Exp Hematol Oncol       Date:  2021-02-16

Review 5.  Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma.

Authors:  Liwei Lv; Yuanbo Liu
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

Review 6.  The emerging role non-coding RNAs in B cell-related disorders.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Elena Jamali
Journal:  Cancer Cell Int       Date:  2022-02-22       Impact factor: 5.722

7.  miRNA Sequence Analysis in Patients With Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Seref Bugra Tuncer; Betul Celik; Demet Akdeniz Odemis; Seda Kılıc Erciyas; Ozge Sukruoglu Erdogan; Mukaddes Avsar; Gozde Kuru Turkcan; Hulya Yazici
Journal:  Pathol Oncol Res       Date:  2022-01-24       Impact factor: 3.201

8.  New biomarkers in peripheral blood of patients with ovarian cancer: high expression levels of miR-16-5p, miR-17-5p, and miR-638.

Authors:  Mukaddes Avsar Saral; Seref Bugra Tuncer; Demet Akdeniz Odemis; Ozge Sukruoglu Erdogan; Seda Kilic Erciyas; Pınar Saip; Sevda Ozel; Hulya Yazici
Journal:  Arch Gynecol Obstet       Date:  2021-08-09       Impact factor: 2.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.